Brazil Was the Trade, but Compute Is Still the Trend

Market regime

The 10/05 tape was a participation test the market passed — but for the wrong reason. The average US stock gained 0.48% on 2,815 advancers to 1,777 decliners, the share holding the 50-day rose again to 31.8% (from 29.4%), and upside support breaks outpaced downside 55 to 26. That is three consecutive sessions of improving internals. Yet the median name is still down ~5% over the past month and 605 stocks sit under RSI 30. This remains a repair, not a recovery: price is being carried by a handful of narratives while the average stock climbs out of a deep hole.

Mega forces

1. The compute capex complex is the only durable bid. Semis are up 17% in a month, semiconductor equipment +22.5%, EDA, data storage and memory-linked funds (PSI +23.5%, SOXX +17.5%, HBMX +17%) all lead. It is the one cluster where fundamentals and price agree: today there is more demand than supply, and the CEO of Nokia said data centers would be built twice as fast without supply constraints. Tech is the only sector with majority 50-day participation (56.7%), and mega-caps hold 56% above the 50-day versus 27% for mid-caps. The differentiation within the group is the signal: components and equipment buyers rose with a capital-scarcity angle, while supply-constrained names (UMC -8.9%, GFS -3.2%, CRDO -2.8%) got hit.

2. AI is moving from story to deployment, and M&A is the monetization. PTC +33.5% on Schneider's $22.6B cash bid, RXO +22.5% on C.H. Robinson's $5.8B offer, onsemi switching to cash for Synaptics, Synopsys announcing a >$1B custom-silicon IP deal with AWS and an OpenAI chip-design model. When acquirers pay cash premiums for software and AI infrastructure, capital is being allocated to compute at almost any price.

3. The political/geographic rotation is real and violent. Brazil's Oct 4 first round (Flavio Bolsonaro ahead 47% to 45%) produced a single-session repricing: EWZ +12.5% on 7.3x volume, the real +4%, EWZS +14.8%, BBD +18.6%, XP +30.9%. Meanwhile Europe (France -7.4%, Germany -5.1% 1M), India (-6.9%) and China (-6.1%) keep bleeding — a dollar and policy problem, not a growth problem.

4. Rates are the quiet risk. The 10-year is 4.63%, the 2s10s spread widened to 0.51, and long-end rate hedging (PFIX) is +30% in a month, the second-best ETF on the board. Long bonds are down 9% over a year. Higher real yields are capping duration, real estate (9% above 50-day, the worst in the market) and utilities.

What's working

Semis and semicap equipment, life science tools (+15%, 79% above 50-day) — a tell that a China-exposed capex cycle is thawing after years of drought — cybersecurity, shipping, and refiners/energy, which is the one cheap group still working. Biotech's rally (ARKG +20%) is real but stock-specific: Genmab and AbbVie posted the first Phase 3 win for a bispecific in frontline DLBCL, and Vaxcyte's PCVX +30.7% on VAX-31 readout. Gold and silver miners, EV makers, solar, uranium, mortgage REITs and vaccine-immune neurology names are where the money is leaving.

Strategy

Own the capex supply chain, not the hype. The cleanest expression is semi equipment, EDA, storage and life-science tools — businesses with pricing power where capital scarcity raises the value of existing capacity. Prefer capital-light AI infrastructure (software, connectors, networking) over high-capex, supply-constrained hardware. Brazilian ADRs carry a real, dated catalyst (Oct 25 runoff), but the 20-30% single-day gaps mean chasing is a bet on the second round, not on value. Avoid duration, precious-metal miners and anything whose thesis depends on falling real yields. If yields break above 5% on the 10-year, expect the narrow compute trade to be the only thing standing between the index and a much broader drawdown.